OPEN ACCESS
EDITED AND REVIEWED BY
Jean-Marc Taymans,
Institut National de la Santé et de la Recherche Médicale (INSERM), France
*CORRESPONDENCE
Chuang-Rung Chang
crchang@life.nthu.edu.tw
SPECIALTY SECTION
This article was submitted to Molecular Signalling and Pathways, a section of the journal Frontiers in Molecular Neuroscience
RECEIVED 07 July 2022
ACCEPTED 15 July 2022
PUBLISHED 01 August 2022
CITATION
Chang J-C, Chen L and Chang C-R (2022) Editorial: Mitochondrial therapy in neurological diseases. Front. Mol. Neurosci. 15:988792. doi: 10.3389/fnmol.2022.988792
COPYRIGHT © 2022 Chang, Chen and Chang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Editorial on the Research Topic
Mitochondrial therapy in neurological diseases

Mitochondrial dysfunction has been implicated in mitochondrial encephalopathy, lactic acidosis and stroke-like episodes (MELAS), brain injury, and neurodegenerative diseases. Difficulty on mitochondrial gene-editing has been one of the major bottlenecks in correcting mitochondria-related disorders. To this end, mitochondrial transplantation presents a new paradigm of therapeutic intervention that benefits neuronal survival and regeneration for neurological diseases. This Research Topic focuses on the mechanistic evidence of mitochondrial dysfunction in neurological diseases and related metabolic disorder, current, and potential therapeutic approaches and supplements.

Mitochondrial function is susceptible to a delicate balance of fusion, fission, and degradation. Li et al. reviewed many faces of electron transport chain (ETC) complex individually affected by Parkinson's Disease (PD)-associated genes. As Figure 1 depicts, in PD, ETC complex regulates neural apoptotic death, mitochondrial cristae structure stability, lysosome function, mitophagy, balance of membrane lipid, oxidative stress, and Lewy body formation, which are the key drivers of PD. Nonetheless, the role of mitochondrial dynamics in PD is rare mentioned largely due to lack the direct evidence. The elongated and uncharacteristically irregular morphology of mitochondria observed in knock-in mice with gene mutation of mitochondrial ubiquinol-cytochrome c reductase core protein 1, a subunit of complex III (Lin et al., 2020), links the association of PD-associated genes and ETC complexes on the direct regulation of mitochondrial morphogenesis.

On the other hand, PD-associated PINK-1 and Alpha-Synuclein (α-Syn) are involved in the balance of mitochondrial \([\text{Ca}^{2+}]\) (Figure 1). PINK-1 deficiency leads to a delayed calcium efflux and mitochondrial calcium overload upon physiological stimulation (Gandhi et al., 2012), whereas α-Syn increases cytosol calcium influx by forming a pore in the plasma membrane (Zakharov et al., 2007). Dysregulation of \([\text{Ca}^{2+}]\) is a major pathological hallmark not only for PD (Ludtmann and Abramov, 2018) but also for the other neurodegeneration diseases (Abeti and Abramov, 2015). Mitochondrial division inhibitor-1 (Mdivi-1) is a candidate...
neuroprotector against ischemia-reperfusion injury after stroke and the machinery is associated with support of mitochondrial function (Nhu et al.). While effect of Mdivi-1 remains controversial (Liu et al., 2015; Ruiz and Alberdi, 2018; Ruiz et al., 2020), its protective machinery in neurons is consistently reported to reduce $[\text{Ca}^{2+}]$ overload (Ruiz and Alberdi, 2018; Ruiz et al., 2020). Moreover, mitochondrial calcium uniporter stabilization preserves energetic homeostasis during Complex I impairment (Balderas et al., 2022). Thus, targeting calcium homeostasis could potentially provide therapeutic cues for neurological diseases.

As mitochondria-cytosol crosstalk buffers cellular ROS and $[\text{Ca}^{2+}]$, mitochondrial PGAM5 protein appears to initiate the action. Role of PGAM5 in mitochondrial morphogenesis and mitophagy have been documented in cancer cells. Its role in the nervous system is still unclear. A review by Liang et al. proposed a functional regulation by PGAM5 in promoting mitochondrial biogenesis and neuronal regeneration after traumatic brain injury (TBI). Stress-induced cleavage of PGAM5 traffic to cytosol, hijacks downstream effectors of WNT signaling and modulates transcription of mitochondrial biogenesis genes. This mechanism echoes a promising therapy of mitochondrial transplantation to partially rescue mitochondrial damage and promote neuronal regeneration.

When comparing the clinical outcome between men and women, women had better outcome after severe TBI. Kalimon and Sullivan nicely compared and discussed the known influence of estrogen, progesterone and testosterone on mitochondrial bioenergetics, glucose utilization at early/acute or later stages after TBI in both rodents and human patients. Estrogen and progesterone obviously take their unusual turn in partying with plasma membrane, mitochondria, and the nucleus. Maintaining cerebral spinal fluid (CSF) is a key for better outcome of TBI. In this aspect, TBI triggers high CSF in male rats whereas CSF in TBI females rats remains low. Glucose utilization and cerebral blood flow in hippocampus varies during different phases of the estrus cycle, suggesting a different susceptibility to glucose utilization and metabolism for males and females upon TBI. These evidence implicate a link between brain injury and metabolism.

Type 2 diabetes mellitus (T2DM) and PD had been demonstrated by a large cohort study that showed PD incidence increased in T2DM patients. Lin et al. reported the effects of an anti-diabetic drug, glucagon-like peptide-1 receptor agonists (GLP-1RAs), on mouse model of PD. Their results suggest possible shared genetic predisposition or pathogenic pathways for both diseases. The protective effect of GLP-1RAs in PD models was shown to involve the activation of GLP-1 receptors and downstream signaling. To this end, liraglutide, a GLP-1RA, was approved by U.S. Food and Drug Administration for treating diabetes, on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD mouse model. MPTP caused parkinsonism through its mitochondrial toxic on respiration complex I. Their results demonstrated that
applying GLP-1RA did provide protection for mouse challenged by MPTP. It reduced the level of blood sugar reduction, protected dopaminergic neurons, and inhibited apoptosis in the substantia nigra caused by MPTP. GLP-1RA restored balance of mitochondria dynamics judged by the change of mitochondrial network from mega to fragmented form. The most significant result of this report is that GLP-1RA reduced α-Syn aggregation in substantia nigra, supporting a neuroprotective effect of the GLP-1RA and its potential as therapeutic agents that link type II diabetes and PD.

Almannai and El-Hattab reviewed the role of nitric oxide (NO) deficiency in mitochondria diseases. Deficiency of NO in mitochondria diseases has been implicated in Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes (MELAS). Since arginine and citrulline are substrates for NO synthesis, taking supplementation of arginine and citrulline could potentially aid patients with mitochondrial disorders resulting from NO deficiency, in particular for stroke-like episodes in patients with MELAS. Similar concept of identifying and characterizing supplements that may benefit mitochondria related neurological disorders is in conjugation with other published articles in this special topic collection.

**Author contributions**

J-CC, LC, and C-RC wrote and revised the manuscript. Figure 1 was generated by J-CC. All authors contributed to the article and approved the submitted version.

**References**

Abeti, R., and Abramov, A. Y. (2015). Mitochondrial Ca2+ in neurodegenerative disorders. *Pharmacol. Res.* 99, 377–381. doi: 10.1016/j.phrs.2015.05.007

Baldaras, E., Eberhardt, D. R., Lee, S., Pleinisi, J. M., Sommackia, S., Balynas, A. M., et al. (2022). Mitochondrial calcium unipporter stabilization preserves energetic homeostasis during complex I impairment. *Nat. Commun.* 13, 1–17. doi: 10.1038/s41467-022-30236-4

Gandhi, S., Vaarmann, A., Yao, Z., Duchen, M. R., Wood, N. W., and Abramov, A. Y. (2012). Dopamine induced neurodegeneration in a PINK1 model of Parkinson’s disease. *PLoS ONE* 7, e37664. doi: 10.1371/journal.pone.0037664

Lin, C. H., Tsai, P. I., Lin, H. Y., Hattori, N., Funayama, M., Jeon, B., et al. (2020). Mitochondrial UQCRC1 mutations cause autosomal dominant parkinsonism with polyneuropathy. *Brain* 143, 3352–3373. doi: 10.1093/brain/awaa279

Liu, J. M., Yi, Z., Liu, S. Z., Chang, J. H., Dang, X. B., Li, Q. Y., et al. (2015). The mitochondrial division inhibitor mdivi-1 attenuates spinal cord ischemia-reperfusion injury both in vitro and in vivo: involvement of BK channels. *Brain Res.* 1619, 155–165. doi: 10.1016/j.brainres.2015.03.033

Ludtmann, M. H., and Abramov, A. Y. (2018). Mitochondrial calcium imbalance in Parkinson’s disease. *Neurosci. Lett.* 663, 86–90. doi: 10.1016/j.neulet.2017.08.044

Ruiz, A., Alberdi, E, and Matute, C. (2018). Mitochondrial division inhibitor 1 (mdivi-1) protects neurons against excitotoxicity through the modulation of mitochondrial function and intracellular Ca2+ signaling. *Front. Mol. Neurosci.* 11, 3. doi: 10.3389/fnmol.2018.00003

Ruiz, A., Quintela-López, T., Sánchez-Gómez, M. V., Gaminde-Blasco, A., Alberdi, E., and Matute, C. (2020). Mitochondrial division inhibitor 1 disrupts oligodendrocyte Ca2+ homeostasis and mitochondrial function. *Glia* 68, 1743–1756. doi: 10.1002/glia.23802

Zakhvorostov, S. D., Hulleman, J. D., Dutseva, E. A., Antonenko, Y. N., Roche, J.-C., and Cramer, W. A. (2007). Helical α-synuclein forms highly conductive ion channels. *Biochemistry* 46, 14369–14379. doi: 10.1021/b701275p

**Funding**

This work was supported by the Ministry of Science of Technology, Taiwan (grant#: MOST 111-2311-B-007-012).

**Acknowledgments**

We thank all scientists who contribute to this Research Topic of Mitochondrial Therapy in Neurological Diseases.

**Conflict of interest**

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s note**

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.